DHPA joined with 215 advocacy groups to voice concern about Medicare Part B proposals outlined in President Trump’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs and corresponding Request for Information (RFI) that could have harmful consequences for patients with serious diseases.
In a letter to HHS Secretary Alex Azar, the groups wrote, “As advocates for both patients reliant on Part B medicines and the physicians and other healthcare professionals who care for them, we are alarmed that proposals to create a new Competitive Acquisition Program (CAP) in Medicare Part B and move Part B medicines under Part D coverage would place middlemen between patients and their doctors and as a result create substantial risk of impeding access to needed care, increasing costs for our nation’s sick and vulnerable patients, and creating new delays and inefficiencies in care delivery.”
Click here to read the full letter.